Overview

Generic Injectables Market is predicted to value over USD xx billion by 2027 end with a CAGR of over xx% during the forecast period 2020 to 2027.

Generic injectables are drugs equivalent to their branded counterparts that do not require any drug patents. These drugs are effective and safe like their innovator drugs as they have similar dosage, active ingredients, quality, strength, form, etc. the research and development cycle of these injectables is shorter and cheaper even though manufacturing them is a complicated process. Furthermore, generic drugs do not require hefty investments as compared to branded drugs who need investments in marketing and research and development. Additionally, there is no stern competition in the generic injectable sector when compared to oral generics. Moreover, many governments are supporting to manufacture generic injectables owing to their various advantages. With rising drug shortages in countries like the United States coupled with several branded drugs facing patent expirations shall bolster the market growth.

Market Segmentation:

By Container Type
•    Vials
•    Premix
•    Prefilled Syringes
•    Ampoules 
•    Others    
By Application
•    Oncology
•    Infectious Diseases
•    Cardiology
•    Diabetes
•    Immunology
•    Others
By Route of Administration
•    Intravenous
•    Intramuscular 
•    Subcutaneous
•    Others
By Region
•    North America
•    Europe
•    Asia-Pacific
•    Latin America
•    Middle East and Africa

The market is categorised into container type, application, route of administration and region. The container type segment is fragmented into vials, premix, prefilled syringes, ampoules and others. The application segment is classified into oncology, infectious diseases, cardiology, diabetes, immunology and others. The route of administration segment is diversified into intravenous, intramuscular, subcutaneous and others.  

Regional Analysis:

The Asia Pacific region is anticipated to lead the market during the forecast period owing to the increased demand of these injectables with the rising incidences of infectious diseases like typhoid, diarrhoea, cholera, malaria and cancers, high insistence for cheaper medical alternatives and a strong presence of key market players in the region. The North America region, on the other hand, is anticipated to proliferate the market during the forecasted timeframe owing to the approval of novel generic injectables and increasing insistence for cheaper biosimilar products along with increased occurrence of lifestyle-oriented diseases.

Competitive Landscape:                            

Some of the key market players associated are Pfizer, Inc., Novartis AG (Sandoz International GmbH), Baxter, Fresenius SE & Co., Mylan N.V., Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC., Lupin Ltd., Sanofi, Biocon.
Pfizer Inc. dominates the global market with over one tenth of the overall market share. Currently, the company is preparing the procedure of developing a formula PF-06881894 which is a biosimilar to Neulasta and which can be used by oncology practitioners. 

FutureWise Key Takeaways:

•    Growth prospects
•    SWOT analysis 
•    Key market trends 
•    Key data-points affecting market growth

Objectives of the Study:

•    To provide with an exhaustive analysis on the global generic injectables market by container type, by application, by route of administration and by region
•    To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
•    To evaluate and forecast micro-markets and the overall market 
•    To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
•    To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions            

Flexible Delivery Model:

•    We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
•    The customization Mobility Care offered are free of charge with purchase of any license of the report
•    You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
           1.1 Objectives of the Study 
           1.2 Market Definition 
           1.3 Market Scope 
                1.3.1 Years Considered for the Study
                1.3.2 Market Covered
           1.4 Currency
           1.5 Limitations 
           1.6 Stakeholders     
2. Research Methodology 
           2.1 Research Data 
                2.1.1 Secondary Data
                        2.1.1.1 Key Data from Secondary Sources
                2.1.2 Primary Data
                        2.1.2.1 Key Data from Primary Sources
           2.2 Market Size Estimation 
           2.3 Market Breakdown and Data Triangulation 
           2.4 Assumptions for the Study  
3. Executive Summary
           3.1 Market Outlook
           3.2 Segment Outlook
           3.3 Competitive Insights
4. Market Variables, Trends & Scope
           4.1 Market Lineage Outlook
           4.2 Penetration and Growth Prospect Mapping
           4.3 Industry Value Chain Analysis
           4.4 Cost Analysis Breakdown
           4.5 Technology Overview
           4.6 Regulatory Framework on Country Level
                4.6.1 Reimbursement Framework    
                4.6.2 Standards and Compliances
5. Market Overview
           5.1 Market Dynamics
                 5.1.1 Market Driver Analysis         
                 5.1.2 Market Restraint Analysis         
                 5.1.3 Industry Challenges                   
6. Market Analysis tools                       
           6.1 Industry Analysis - Porter’s
                     6.1.1 Supplier Power
                     6.1.2 Buyer Power
                     6.1.3 Substitution Threat
                     6.1.4 Threat from new entrants
                     6.1.5 Competitive Rivalry                  
           6.2 Pestel Analysis
                     6.2.1 Political Landscape
                     6.2.2 Environmental Landscape
                     6.2.3 Social landscape
                     6.2.4 Technology landscape
                     6.2.5 Legal Landscape
7. Generic Injectables Market, By Container Type Historical Analysis 2015 to 2019 and Forecast 2020-2027 (USD million)
           7.1 Vials
           7.2 Premix
           7.3 Prefilled Syringes
           7.4 Ampoules 
           7.5 Others                        
8. Generic Injectables Market, By Application Historical Analysis 2015 to 2019 and Forecast 2020-2027 (USD million)
           8.1 Oncology
           8.2 Infectious Diseases
           8.3 Cardiology
           8.4 Diabetes
           8.5 Immunology
           8.6 Others         
9. Generic Injectables Market, By Route of Administration Historical Analysis 2015 to 2019 and Forecast 2020-2027 (USD million)
           9.1 Intravenous
           9.2 Intramuscular 
           9.3 Subcutaneous
           9.4 Others
10. North America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
           10.1. Introduction
           10.2. Historical Market Size (USD Mn) Analysis By Country, 2015-2019
                10.2.1. U.S.
                10.2.2. Canada
                10.2.3. Mexico 
                10.2.4. Rest of North America
           10.3 Market Size (USD Mn) Forecast for North America 2020-2027
11. Latin America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
           11.1. Introduction
           11.2. Regional Market Trends
           11.3. Historical Market Size (US$ Mn) Analysis By Country, 2015-2019
                11.3.1. Brazil
                11.3.2. Venezuela
                11.3.3. Argentina
                11.3.4. Rest of Latin America
           11.4 Market Size (US$ Mn) Forecast for Latin America 2020-2027
12. Europe Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
           12.1. Introduction
           12.2. Historical Market Size (US$ Mn) Analysis By Country, 2015-2019
                12.2.1. Germany
                12.2.2. U.K
                12.2.3. France
                12.2.4. Italy
                12.2.5 Switzerland
                12.2.6. Spain
                12.2.7. Russia
                12.2.8. Poland
                12.2.9. Rest of Western Europe
           12.3 Market Size (US$ Mn) Forecast for Europe 2020-2027
13. Asia Pacific Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
            13.1 Introduction
            13.2 Historical Market Size (USD Mn) Analysis By Country, 2015-2019
                 13.2.1 Japan
                 13.2.2 China
                 13.2.3 Singapore
                 13.2.4 Korea         
                 13.2.5 India
                 13.2.6 Australia and New Zealand
                 13.2.7 ASEAN
                 13.2.8 Rest of Asia Pacific
            13.3 Market Size (US$ Mn) Forecast for Asia Pacific 2020-2027
14. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
    14.1 Introduction
    14.2 Historical Market Size (USD Mn) Analysis By Country, 2015-2019
        14.2.1 UAE
        14.2.2 South Africa
        14.2.3 Egypt
        14.2.4 Saudi Arabia
        14.2.5 Rest of MEA
    14.3 Market Size (US$ Mn) Forecast for MEA 2020-2027
15. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts)
    15.1 Novartis AG (Sandoz International GmbH)
            15.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.1.2. Product Portfolio
            15.1.3. SWOT Analysis
            15.1.4. Financial Overview
            15.1.5. Strategic Overview
    15.2 Baxter
              15.2.1. Company Overview (HQ, Business Segments, Employee Strength)
              15.2.2. Product Portfolio
              15.2.3. SWOT Analysis
              15.2.4. Financial Overview
              15.2.5. Strategic Overview
    15.3 Fresenius SE & Co.
              15.3.1. Company Overview (HQ, Business Segments, Employee Strength)
              15.3.2. Product Portfolio
              15.3.3. SWOT Analysis
              15.3.4. Financial Overview
              15.3.5. Strategic Overview
    15.4 Mylan N.V.
              15.4.1. Company Overview (HQ, Business Segments, Employee Strength)
              15.4.2. Product Portfolio
              15.4.3. SWOT Analysis
              15.4.4. Financial Overview
              15.4.5. Strategic Overview
    15.5 Teva Pharmaceutical Industries Ltd.
              15.5.1. Company Overview (HQ, Business Segments, Employee Strength)
              15.5.2. Product Portfolio
              15.5.3. SWOT Analysis
              15.5.4. Financial Overview
              15.5.5. Strategic Overview
    15.6 Hikma Pharmaceuticals PLC.
              15.6.1. Company Overview (HQ, Business Segments, Employee Strength)
              15.6.2. Product Portfolio
              15.6.3. SWOT Analysis
              15.6.4. Financial Overview
              15.6.5. Strategic Overview
    15.7 Pfizer Inc.
             15.7.1. Company Overview (HQ, Business Segments, Employee Strength)
             15.7.2. Product Portfolio
             15.7.3. SWOT Analysis
             15.7.4. Financial Overview
             15.7.5. Strategic Overview
    15.8 Lupin Ltd.
              15.8.1. Company Overview (HQ, Business Segments, Employee Strength)
              15.8.2. Product Portfolio
              15.8.3. SWOT Analysis
              15.8.4. Financial Overview
              15.8.5. Strategic Overview    
    15.9 Sanofi
              15.9.1. Company Overview (HQ, Business Segments, Employee Strength)
              15.9.2. Product Portfolio
              15.9.3. SWOT Analysis
              15.9.4. Financial Overview
              15.9.5. Strategic Overview
    15.10 Biocon
              15.10.1. Company Overview (HQ, Business Segments, Employee Strength)
              15.10.2. Product Portfolio
              15.10.3. SWOT Analysis
              15.10.4. Financial Overview
              15.10.5. Strategic Overview
16. Impact of COVID-19
     16.1. Positive influence on the healthcare industry
     16.2. The financial disruption of the manufacturing sector
     16.3. Impact of COVID-19 on emerging companies
     16.4. Significant mandates in the healthcare regulations initiated by administrations
     16.5. The overall economic slowdown of the developing and developed nations
17. Competitive Intelligence and Competitive Matrix
     17.1 Competitive Intelligence
     17.2 Competitive Matrix
18. Major Deals and Strategic Alliances Analysis
     18.1 Joint ventures
     18.2 Mergers and acquisitions              
     18.3 Licensing and partnerships
     18.4 Technology Collaborations
     18.5 Strategic Divestments
     18.6 Market Entry Strategies                        
19. Relevant Case Studies and Latest News Updates
20. Key Market Takeaway Points from the Market Analysts at Future Market Analytics 

Tables

Figures